NO20001219D0 - Mixture for drug administration - Google Patents

Mixture for drug administration

Info

Publication number
NO20001219D0
NO20001219D0 NO20001219A NO20001219A NO20001219D0 NO 20001219 D0 NO20001219 D0 NO 20001219D0 NO 20001219 A NO20001219 A NO 20001219A NO 20001219 A NO20001219 A NO 20001219A NO 20001219 D0 NO20001219 D0 NO 20001219D0
Authority
NO
Norway
Prior art keywords
mixture
drug administration
administration
drug
Prior art date
Application number
NO20001219A
Other languages
Norwegian (no)
Other versions
NO20001219L (en
Inventor
Lisbeth Illum
Yu-Hui Cheng
Peter James Watts
Stanley Steward Davis
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of NO20001219L publication Critical patent/NO20001219L/en
Publication of NO20001219D0 publication Critical patent/NO20001219D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20001219A 1997-09-09 2000-03-09 Mixture for drug administration NO20001219D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system
PCT/GB1998/002692 WO1999012549A2 (en) 1997-09-09 1998-09-07 Controlled release microsphere delivery system

Publications (2)

Publication Number Publication Date
NO20001219L NO20001219L (en) 2000-03-09
NO20001219D0 true NO20001219D0 (en) 2000-03-09

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001219A NO20001219D0 (en) 1997-09-09 2000-03-09 Mixture for drug administration

Country Status (10)

Country Link
EP (1) EP1011680A2 (en)
JP (1) JP2001515862A (en)
AR (1) AR017079A1 (en)
AU (1) AU745511B2 (en)
CA (1) CA2302762A1 (en)
GB (1) GB9718986D0 (en)
NO (1) NO20001219D0 (en)
NZ (1) NZ502710A (en)
WO (1) WO1999012549A2 (en)
ZA (1) ZA987762B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
ES2169980B1 (en) * 1999-12-17 2003-11-01 Lipotec Sa MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
WO2004000363A1 (en) 2002-06-25 2003-12-31 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
MXPA05004721A (en) * 2002-10-31 2005-08-03 Pfizer Prod Inc Solid and semi-solid polymeric ionic conjugates.
UA82561C2 (en) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Controlled release sterile aripiprazole formulation for injections, method for preparing aripiprazole formulation, and method for treating schizophrenia
MXPA06011924A (en) 2004-04-15 2007-06-11 Alkermes Inc Polymer-based sustained release device.
CA2577852A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
PL2359808T3 (en) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies
EA200970348A1 (en) * 2006-10-05 2009-10-30 Панацея Биотек Лтд. NEW INJECTABLE DEPOSIT COMPOSITIONS AND METHOD OF OBTAINING SUCH COMPOSITIONS
WO2008075762A1 (en) 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2170279B1 (en) 2007-07-31 2017-12-27 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
DK2240155T3 (en) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Devices, formulations and methods for the delivery of several beneficial agents
KR101823699B1 (en) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
CA2816288C (en) * 2010-11-25 2016-01-26 Shandong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (en) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd Freeze-dried aripiprazole formulation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (en) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Implant placement and removal systems.
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
KR102045721B1 (en) * 2019-03-27 2019-11-18 주식회사 씨트리 Compositions of dispersion phase for preparation of apixaban loaded microsphere and biocompatible polymer based apixaban loaded microsphere prepared therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine

Also Published As

Publication number Publication date
AU8992598A (en) 1999-03-29
AU745511B2 (en) 2002-03-21
WO1999012549A3 (en) 1999-05-06
WO1999012549A2 (en) 1999-03-18
AR017079A1 (en) 2001-08-22
CA2302762A1 (en) 1999-03-18
GB9718986D0 (en) 1997-11-12
JP2001515862A (en) 2001-09-25
ZA987762B (en) 2000-02-28
NZ502710A (en) 2001-09-28
EP1011680A2 (en) 2000-06-28
NO20001219L (en) 2000-03-09

Similar Documents

Publication Publication Date Title
NO20001219D0 (en) Mixture for drug administration
NO994003L (en) Pharmaceutical mixture
NO975931D0 (en) Mixture for administration of drug
ID23874A (en) DRUG
NO992427D0 (en) Pharmaceutical surface mixture
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
FI972292A0 (en) Administration of diabetes
DK0797991T3 (en) Delayed-release drug formulation
DK1035833T3 (en) Composition for nasal administration
EE9700241A (en) Pharmaceutical composition for transdermal administration
DE69821457D1 (en) Controlled drug delivery compositions
PL328399A1 (en) Drug administration aid
DE69935681D1 (en) Devices for drug administration
FI971279A (en) Drug
KR950700754A (en) New drugs (NOVEL MEDICAMENT)
NO20001014D0 (en) Dermatological mixture
BR9610396A (en) Pharmaceutical formulation
FR2767121B1 (en) DISTRIBUTOR OF DRUGS
DE69810189T2 (en) Controlled drug delivery compositions
NO995251D0 (en) Procedure for administering halotherapy
DK0868911T3 (en) Rapamycin preparations for oral administration
NO995039L (en) Gastric retained pharmaceutical preparation
NO994619L (en) Pharmaceutical mixtures
NO992999D0 (en) Pharmaceutical surface preparation for oral administration
BR9607433A (en) Pharmaceutical composition for parental administration

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application